MDGA2

Summary

MDGA2 (MAM domain containing glycosylphosphatidylinositol anchor 2, HGNC:19835) is a protein-coding gene on chromosome 14q21.3, encoding MAM domain-containing glycosylphosphatidylinositol anchor protein 2 (Q7Z553). May be involved in cell-cell interactions.

Predicted to be involved in regulation of synapse organization and spinal cord motor neuron differentiation. Predicted to act upstream of or within several processes, including motor behavior; negative regulation of neuron apoptotic process; and neuron migration. Predicted to be located in extracellular region and plasma membrane. Predicted to be active in GABA-ergic synapse; glutamatergic synapse; and postsynaptic density membrane.

Source: NCBI Gene 161357 — RefSeq curated summary.

At a glance

• GWAS associations: 18
• Clinical variants (ClinVar): 62 total — 1 likely-pathogenic
• Cancer driver (intOGen): activating (oncogene-like) across 1 cancer types
• MANE Select transcript: NM_001113498

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19835
Approved symbol	MDGA2
Name	MAM domain containing glycosylphosphatidylinositol anchor 2
Location	14q21.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000139915
Ensembl biotype	protein_coding
OMIM	611128
Entrez	161357

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 4 protein_coding, 2 nonsense_mediated_decay, 2 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000357362, ENST00000399232, ENST00000472499, ENST00000482848, ENST00000486952, ENST00000554762, ENST00000555521, ENST00000557238, ENST00000557516

RefSeq mRNA: 2 — MANE Select: NM_001113498 NM_001113498, NM_182830

CCDS: CCDS41948, CCDS45098

Canonical transcript exons

ENST00000399232 — 17 exons

Exon	Start	End
ENSE00001430877	47674517	47675605
ENSE00001537098	46840092	46842019
ENSE00003703537	46855024	46855154
ENSE00003703744	47144078	47144274
ENSE00003704817	47218021	47218195
ENSE00003705552	47131714	47131846
ENSE00003705752	46845766	46845871
ENSE00003705794	46882044	46882221
ENSE00003706626	46873433	46873591
ENSE00003707355	46877489	46877509
ENSE00003707948	47301411	47301550
ENSE00003708881	47096854	47097123
ENSE00003709807	46874045	46874200
ENSE00003709928	46920012	46920160
ENSE00003710181	47061249	47061578
ENSE00003710533	47035011	47035304
ENSE00003711265	46957374	46957643

Expression profiles

Bgee: expression breadth broad, 85 present calls, max score 84.63.

FANTOM5 (CAGE): breadth broad, TPM avg 3.1512 / max 421.6553, expressed in 387 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
143066	2.4759	339
143063	0.2683	94
143064	0.1798	80
143065	0.1733	82
143061	0.0539	32

Top tissues by expression

202 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	84.63	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.82	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.25	gold quality
ventricular zone	UBERON:0003053	72.14	gold quality
prefrontal cortex	UBERON:0000451	70.56	gold quality
secondary oocyte	CL:0000655	68.21	silver quality
corpus callosum	UBERON:0002336	67.33	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	65.60	gold quality
ganglionic eminence	UBERON:0004023	65.52	gold quality
frontal cortex	UBERON:0001870	64.63	gold quality
neocortex	UBERON:0001950	64.60	gold quality
spinal cord	UBERON:0002240	63.90	gold quality
Brodmann (1909) area 9	UBERON:0013540	63.61	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	63.34	gold quality
testis	UBERON:0000473	63.32	gold quality
stromal cell of endometrium	CL:0002255	62.91	gold quality
primary visual cortex	UBERON:0002436	62.65	gold quality
adrenal tissue	UBERON:0018303	62.58	gold quality
left testis	UBERON:0004533	62.49	gold quality
anterior cingulate cortex	UBERON:0009835	62.46	gold quality
cerebral cortex	UBERON:0000956	62.23	gold quality
right testis	UBERON:0004534	60.82	gold quality
hypothalamus	UBERON:0001898	60.55	gold quality
right frontal lobe	UBERON:0002810	59.48	gold quality
occipital lobe	UBERON:0002021	59.38	gold quality
amygdala	UBERON:0001876	59.00	gold quality
superior frontal gyrus	UBERON:0002661	58.59	gold quality
forebrain	UBERON:0001890	57.52	gold quality
Brodmann (1909) area 46	UBERON:0006483	56.72	silver quality
Ammon’s horn	UBERON:0001954	56.71	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	3136.12
E-GEOD-180759	yes	2903.69
E-HCAD-25	yes	19.23
E-ANND-3	yes	5.83
E-GEOD-93593	yes	4.38

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
CDKN1A	Activation
TP53	Activation

Upstream regulators (CollecTRI, top): KLF6

miRNA regulators (miRDB)

193 targeting MDGA2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-3912-5P	99.95	66.11	925
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-10523-5P	99.91	69.22	2038
HSA-MIR-498-3P	99.91	71.27	1114

Literature-anchored findings (GeneRIF, showing 7)

• MAMDC1 gene is implicated in neuroticism. (PMID:18762592)
• No association of rs7151262 with neuroticism was found (PMID:19440164)
• A novel uncharacterized gene, MAMDC1 (MAM domain containing glycosylphosphatidylinositol anchor 2, also known as MDGA2, MIM 611128), represents a putative susceptibility gene for systemic lupus erythematosus. (PMID:19997561)
• This finding provides further support for a link between variants in the MDGA2 gene and specific neuroticism-related phenotypes. (PMID:21399569)
• This study demonistrated suggested taht Rostral growth of commissural axons requires the cell adhesion molecule MDGA2 (PMID:21542908)
• Polymorphisms of rs961616 in MAMDC1 gene were associated with rash and photosensitivity, but not disease risk, of systemic lupus erythematosus in Chinese population. (PMID:21660437)
• A novel tumour suppressor gene, MDGA2, which is frequently inactivated by promoter methylation in Gastric cancer was identified. Promoter hypermethylation of MDGA2 represents a prognostic biomarker in patients with early stage Gastric cancer. (PMID:26206665)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	mdga2a	ENSDARG00000024017
		ENSDARG00000112111
mus_musculus	Mdga2	ENSMUSG00000034912
rattus_norvegicus	Mdga2	ENSRNOG00000000618

Paralogs (4): MDGA1 (ENSG00000112139), MAMDC2 (ENSG00000165072), MAMDC4 (ENSG00000177943), MALRD1 (ENSG00000204740)

Protein

Protein identifiers

MAM domain-containing glycosylphosphatidylinositol anchor protein 2 — Q7Z553 (reviewed: Q7Z553)

Alternative names: MAM domain-containing protein 1

All UniProt accessions (5): Q7Z553, E9PMG9, G3V5U0, G3V5Z1, H0YJ52

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in cell-cell interactions.

Subunit / interactions. Interacts (through the Ig-like domains) with NLGN2.

Subcellular location. Cell membrane.

Tissue specificity. Detected in Leydig cells, syncytiotrophoblast, duodenal villi epithelial cells and neutrophils from kidney and cutaneous squamous cell carcinoma (at protein level).

Isoforms (3)

UniProt ID	Names	Canonical?
Q7Z553-1	1	yes
Q7Z553-2	2
Q7Z553-3	3

RefSeq proteins (2): NP_001106970, NP_878250 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000998	MAM_dom	Domain
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR003961	FN3_dom	Domain
IPR007110	Ig-like_dom	Domain
IPR013098	Ig_I-set	Domain
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036116	FN3_sf	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050958	Cell_Adh-Cytoskel_Orgn	Family

Pfam: PF00629, PF07679, PF13927

UniProt features (37 total): domain 8, glycosylation site 8, sequence conflict 8, disulfide bond 6, splice variant 2, signal peptide 1, chain 1, lipid moiety-binding region 1, propeptide 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7Z553-F1	84.96	0.56

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 931

Disulfide bonds (6): 62–110, 159–216, 264–310, 359–417, 465–515, 561–611

Glycosylation sites (8): 92, 213, 237, 434, 443, 504, 610, 703

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-163125	Post-translational modification: synthesis of GPI-anchored proteins
R-HSA-392499	Metabolism of proteins
R-HSA-597592	Post-translational protein modification

MSigDB gene sets: 162 (showing top): GOBP_SPINAL_CORD_DEVELOPMENT, GOBP_NEUROGENESIS, TAKADA_GASTRIC_CANCER_COPY_NUMBER_DN, GOBP_CELL_DIFFERENTIATION_IN_SPINAL_CORD, GOBP_SPINAL_CORD_MOTOR_NEURON_DIFFERENTIATION, AGGCACT_MIR5153P, GOBP_VENTRAL_SPINAL_CORD_DEVELOPMENT, GTGCCTT_MIR506, DAWSON_METHYLATED_IN_LYMPHOMA_TCL1, AAACCAC_MIR140, NF1_Q6_01, IRF1_Q6, CAATGCA_MIR33, GOBP_CENTRAL_NERVOUS_SYSTEM_NEURON_DIFFERENTIATION, AAAGACA_MIR511

GO Biological Process (2): nervous system development (GO:0007399), spinal cord motor neuron differentiation (GO:0021522)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (4): extracellular region (GO:0005576), plasma membrane (GO:0005886), side of membrane (GO:0098552), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Post-translational protein modification	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
membrane	2
system development	1
cell differentiation in spinal cord	1
ventral spinal cord development	1
central nervous system neuron differentiation	1
binding	1
cell periphery	1
leaflet of membrane bilayer	1

Protein interactions and networks

STRING

1342 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MDGA2	NLGN2	Q8NFZ4	721
MDGA2	NLGN1	Q8N2Q7	616
MDGA2	SPPL2C	Q8IUH8	576
MDGA2	PDE4D	Q08499	501
MDGA2	FN1	P02751	469
MDGA2	SIGLEC15	Q6ZMC9	463
MDGA2	PRSS35	Q8N3Z0	458
MDGA2	PTPRM	P28827	451
MDGA2	GALNT13	Q8IUC8	450
MDGA2	DCLK1	O15075	437
MDGA2	NLGN3	Q9NZ94	431
MDGA2	MRTFB	Q9ULH7	426
MDGA2	HS3ST5	Q8IZT8	423
MDGA2	FBXO33	Q7Z6M2	422
MDGA2	CCL26	Q9Y258	419

IntAct

2 interactions, top by confidence:

A	B	Type	Score
MRPL12	GTPBP10	psi-mi:“MI:0914”(association)	0.350

BioGRID (7): MDGA2 (Affinity Capture-RNA), MDGA2 (Affinity Capture-RNA), MDGA2 (Co-fractionation), MDGA2 (Co-fractionation), NCKAP5L (Co-fractionation), SLC38A7 (Co-fractionation), MDGA2 (Affinity Capture-RNA)

ESM2 similar proteins: A0A8M2B818, A3KPA0, B0JYH6, O55005, O89026, O94898, P0DPA2, P16170, P17790, P36335, P40190, P57087, P57097, P60755, P60756, P85171, Q00560, Q0PMG2, Q0WYX8, Q12866, Q15198, Q15223, Q1WIM2, Q2PFX1, Q52KR2, Q58EG3, Q5BIP2, Q5RJP7, Q60805, Q61490, Q66KX2, Q68FQ2, Q6DJ83, Q6P3A4, Q6PE55, Q6X936, Q7Z553, Q7ZXX1, Q80W68, Q8BLQ9

Diamond homologs: A2AJX4, B3EWZ5, B3EWZ6, B3EX02, C0HL13, O75581, O88572, P35953, P60755, P60756, P85171, P97435, P98072, P98073, P98074, Q0PMG2, Q0WYX8, Q2PC93, Q5VYJ5, Q7Z553, Q8NFP4, Q8QFX6, Q9GMT4, O14786, O35375, P28824, P28825, P79795, P97333, Q16820, Q61847, Q64230, Q9QWJ9, A2ARV4, O14522, O60462, P35822, P98157, P98158, P98164

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
MDGA2	down-regulates	Proliferation
MDGA2	“up-regulates quantity by stabilization”	DMAP1	binding
MDGA2	“up-regulates quantity by expression”	TP53	“transcriptional regulation”
MDGA2	“up-regulates quantity by expression”	CDKN1A	“transcriptional regulation”

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 1 cancer types — MEL.

Clinical variants and AI predictions

ClinVar

62 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	46
Likely benign	2
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1708469	NM_001113498.3(MDGA2):c.278_279dup (p.Ala94fs)	Likely pathogenic

SpliceAI

4551 predictions. Top by Δscore:

Variant	Effect	Δscore
14:46845757:GATAC:G	donor_loss	1.0000
14:46845758:ATACT:A	donor_loss	1.0000
14:46845759:TACTT:T	donor_loss	1.0000
14:46845760:ACT:A	donor_loss	1.0000
14:46845761:CT:C	donor_loss	1.0000
14:46845762:TT:T	donor_loss	1.0000
14:46845763:TA:T	donor_loss	1.0000
14:46845764:A:AC	donor_gain	1.0000
14:46845764:ACT:A	donor_gain	1.0000
14:46845764:ACTC:A	donor_loss	1.0000
14:46845765:C:CC	donor_gain	1.0000
14:46845765:C:G	donor_loss	1.0000
14:46845765:CT:C	donor_gain	1.0000
14:46845765:CTC:C	donor_gain	1.0000
14:46845765:CTCTT:C	donor_gain	1.0000
14:46845868:TGAG:T	acceptor_gain	1.0000
14:46873593:T:C	acceptor_gain	1.0000
14:46874040:CATA:C	donor_loss	1.0000
14:46874043:A:C	donor_loss	1.0000
14:46874044:CC:C	donor_loss	1.0000
14:46874044:CCTT:C	donor_gain	1.0000
14:46874047:T:A	donor_gain	1.0000
14:46874198:CTC:C	acceptor_gain	1.0000
14:46874201:C:CC	acceptor_gain	1.0000
14:46877487:A:AC	donor_gain	1.0000
14:46877488:C:CC	donor_gain	1.0000
14:46882040:TTA:T	donor_loss	1.0000
14:46882041:TACC:T	donor_gain	1.0000
14:46882042:A:AC	donor_gain	1.0000
14:46882042:AC:A	donor_gain	1.0000

AlphaMissense

6647 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:46855066:C:A	W878C	1.000
14:46855066:C:G	W878C	1.000
14:46855068:A:G	W878R	1.000
14:46855068:A:T	W878R	1.000
14:46874127:C:A	W768C	1.000
14:46874127:C:G	W768C	1.000
14:46874129:A:G	W768R	1.000
14:46874129:A:T	W768R	1.000
14:46882103:A:G	L717P	1.000
14:46920074:A:G	W657R	1.000
14:46920074:A:T	W657R	1.000
14:46957530:A:G	W576R	1.000
14:46957530:A:T	W576R	1.000
14:47035016:A:T	V536D	1.000
14:47035078:A:C	C515W	1.000
14:47035080:A:G	C515R	1.000
14:47035086:A:C	Y513D	1.000
14:47035192:C:A	W477C	1.000
14:47035192:C:G	W477C	1.000
14:47035194:A:G	W477R	1.000
14:47035194:A:T	W477R	1.000
14:47035230:A:G	C465R	1.000
14:47061316:A:C	C417W	1.000
14:47061317:C:T	C417Y	1.000
14:47061318:A:G	C417R	1.000
14:47061324:A:C	Y415D	1.000
14:47061329:C:T	G413E	1.000
14:47061330:C:A	G413W	1.000
14:47061335:T:A	D411V	1.000
14:47061335:T:C	D411G	1.000

dbSNP variants (sampled 300 via entrez): RS1000010745 (14:46866629 T>C), RS1000014846 (14:47399765 TA>T,TAA), RS1000015536 (14:47417935 A>G), RS1000016283 (14:47127534 G>C,T), RS1000018385 (14:47406676 C>A,T), RS1000018405 (14:47586541 C>T), RS1000021031 (14:47531162 G>A), RS1000028480 (14:47135871 C>G,T), RS1000029684 (14:47625581 T>C), RS1000037307 (14:47252001 G>A,T), RS1000040421 (14:47088577 A>G,T), RS1000041444 (14:47009571 C>T), RS1000044300 (14:47199663 T>C), RS1000045762 (14:46910741 C>T), RS1000048935 (14:47080831 A>G)

Disease associations

OMIM: gene MIM:611128 | disease phenotypes: MIM:615873

GenCC curated gene-disease

Mondo (2): intellectual disability (MONDO:0001071), ADNP-related multiple congenital anomalies - intellectual disability - autism spectrum disorder (MONDO:0014379)

Orphanet (2): Helsmoortel-Van der Aa syndrome (Orphanet:404448), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

18 associations (top):

Study	Trait	p-value
GCST000080_13	Hemostatic factors and hematological phenotypes	2.000000e-07
GCST000226_1	Neuroticism	7.000000e-07
GCST001453_1	Sexual dysfunction (SSRI/SNRI-related)	3.000000e-07
GCST001476_13	Response to tocilizumab in rheumatoid arthritis	2.000000e-07
GCST001762_141	Obesity-related traits	3.000000e-07
GCST001974_2	Idiopathic pulmonary fibrosis	4.000000e-06
GCST003059_18	Parkinson’s disease	1.000000e-06
GCST003262_530	Post bronchodilator FEV1	3.000000e-06
GCST003264_1369	Post bronchodilator FEV1/FVC ratio	8.000000e-08
GCST003784_14	Multiple system atrophy	4.000000e-06
GCST004744_4	Lung adenocarcinoma	3.000000e-06
GCST005566_20	Insomnia	3.000000e-07
GCST006427_32	Depression in smokers	4.000000e-06
GCST006460_11	Bronchopulmonary dysplasia in preterm infants	3.000000e-06
GCST007001_7	Cerebrospinal AB1-42 levels in normal cognition	5.000000e-07
GCST008476_11	Emphysema annual change measurement in smokers (percent low attenuation area)	8.000000e-06
GCST010988_537	Adult body size	9.000000e-14
GCST90000047_248	Age at first sexual intercourse	2.000000e-12

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0004714	sexual dysfunction
EFO:0004810	interleukin-6 measurement
EFO:0000768	idiopathic pulmonary fibrosis
EFO:0004314	forced expiratory volume
EFO:0004713	FEV/FVC ratio
EFO:0004670	beta-amyloid 1-42 measurement
EFO:0007626	emphysema imaging measurement
EFO:0009749	age at first sexual intercourse measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs1160351	Toxicity	3	fluvoxamine;milnacipran;paroxetine	Major Depressive Disorder

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs1160351	MDGA2	3	0.00	1	fluvoxamine;milnacipran;paroxetine

CTD chemical–gene interactions

14 total (human), top 14 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects splicing, decreases expression	2
Aflatoxin B1	decreases expression, decreases methylation	2
aristolochic acid I	decreases expression	1
methyleugenol	decreases expression	1
trichostatin A	increases expression	1
CGP 52608	affects binding, increases reaction	1
bisphenol S	decreases methylation	1
Resveratrol	decreases expression, affects cotreatment	1
Sunitinib	increases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Lead	affects expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Triclosan	decreases expression	1
Valproic Acid	increases expression	1

Clinical trials (associated diseases)

199 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)
NCT02721394	Not specified	UNKNOWN	FCT With Young Children With ID in the UK: A Feasibility Project V.1
NCT02746614	Not specified	COMPLETED	Psychomotor Therapy Effects in Adaptive Behavior and Motor Proficiency in Intellectual Disability
NCT02836405	Not specified	COMPLETED	TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders